document.write('<div class="rss_box">');
document.write('<ul class="rss_items">');
document.write('<li class="rss_item"><a class="rss_item" href="http://www.topix.net/drug/herceptin/2010/09/swog-names-five-cancer-researchers-as-outstanding-young-investigators?fromrss=1"  target="feed">SWOG Names Five Cancer Researchers as Outstanding Young Investigators</a>');
document.write('<br /><p>The Southwest Oncology Group, or SWOG, one of the nation\'s largest cancer clinical trials networks, has selected five talented researchers who are early in their careers for its 2010 Young Investigator Training Course .</p>');
document.write('</li>');
document.write('<li class="rss_item"><a class="rss_item" href="http://www.topix.net/drug/herceptin/2010/09/targeting-tumors-research-has-led-to-lifesaving-breast-cancer-treatments?fromrss=1"  target="feed">Targeting tumors: Research has led to lifesaving breast cancer treatments</a>');
document.write('<br /><p>Dr. Rita Mehta\'s research has led to more effective breast cancer treatments, with lifesaving results.</p>');
document.write('</li>');
document.write('<li class="rss_item"><a class="rss_item" href="http://www.topix.net/drug/herceptin/2010/09/bad-news-for-breast-cancer-patients?fromrss=1"  target="feed">Bad news for breast cancer patients</a>');
document.write('<br /><p>HER2-positive breast cancer is an extremely aggressive form of carcinoma. It is difficult to diagnose and carries a significant risk of relapse.</p>');
document.write('</li>');
document.write('<li class="rss_item"><a class="rss_item" href="http://www.topix.net/drug/herceptin/2010/09/roche-provides-update-on-fda-application-for-t-dm1?fromrss=1"  target="feed">Roche Provides Update On FDA Application For T-DM1</a>');
document.write('<br /><p>Clinical Trials / Drug Trials Roche announced that the U.S. Food and Drug Administration issued a Refuse to File letter for accelerated approval for the company\'s trastuzumab-DM1 Biologics License Application .</p>');
document.write('</li>');
document.write('<li class="rss_item"><a class="rss_item" href="http://www.topix.net/drug/herceptin/2010/08/why-did-my-stock-just-die?fromrss=1"  target="feed">Why Did My Stock Just Die?</a>');
document.write('<br /><p>Your stock just took a nosedive -- but don\'t panic. First, let\'s see whether it had good reason to fall.</p>');
document.write('</li>');
document.write('<li class="rss_item"><a class="rss_item" href="http://www.topix.net/drug/herceptin/2010/08/genentech-receives-refuse-to-file-letter-from-fda-for-t-dm1?fromrss=1"  target="feed">Genentech Receives Refuse To File Letter From FDA For T-DM1</a>');
document.write('<br /><p>ImmunoGen, Inc. , a biotechnology company that develops antibody-based targeted anticancer products, announced that Genentech, a member of the Roche Group, announced its receipt of a Refuse to File letter from the US Food and Drug Administration for the accelerated approval of the Biologic License Application for trastuzumab-DM1, or T-DM1, ...</p>');
document.write('</li>');
document.write('<li class="rss_item"><a class="rss_item" href="http://www.topix.net/drug/herceptin/2010/08/the-expression-of-activated-y-box-binding-protein-1-serine-102?fromrss=1"  target="feed">The expression of activated Y-box binding protein-1 serine 102...</a>');
document.write('<br /><p>The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44 &amp;#x0002B; cells 1Department of Medicine, Experimental Medicine Program, Vancouver, British Columbia, Canada 2Laboratory of Oncogenomic Research, Department of Pediatrics, Child and Family Research Institute, ...</p>');
document.write('</li>');
document.write('<li class="rss_item"><a class="rss_item" href="http://www.topix.net/drug/herceptin/2010/08/trastuzumab-with-chemotherapy-for-advanced-gastric-or-gastrooesophageal-junction-cancer?fromrss=1"  target="feed">Trastuzumab with chemotherapy for advanced gastric or gastrooesophageal junction cancer</a>');
document.write('<br /><p>Trastuzumab with chemotherapy can be considered as a new standard option for patients with HER2-positive advanced gastric or gastroesophageal junction cancer, reports a study in The Lancet .</p>');
document.write('</li>');
document.write('<li class="rss_item"><a class="rss_item" href="http://www.topix.net/drug/herceptin/2010/08/genentech-provides-update-on-fda-application-for-t-dm1?fromrss=1"  target="feed">Genentech Provides Update On FDA Application For T-DM1</a>');
document.write('<br /><p>Genentech, a member of the Roche Group , announced the U.S. Food and Drug Administration issued a Refuse to File letter for accelerated approval for the company\'s trastuzumab-DM1 Biologics License Application .</p>');
document.write('</li>');
document.write('<li class="rss_item"><a class="rss_item" href="http://www.topix.net/drug/herceptin/2010/08/genentech-caught-off-guard-fda-issues-refuse-to-file-for-t-dm1?fromrss=1"  target="feed">Genentech Caught off Guard, FDA Issues Refuse-to-File for T-DM1</a>');
document.write('<br /><p>The FDA sent a refuse-to-file letter to Genentech Inc., a member of the Roche Group, rejecting the company\'s application for accelerated approval of trastuzumab-DM1 and catching investors and the company off guard.</p>');
document.write('</li>');
document.write('</ul></div>');
document.close();